|
rs121913377
|
|
TT |
0.770 |
GeneticVariation |
CLINVAR |
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.
|
22281684 |
2012 |
|
rs397517132
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.
|
22281684 |
2012 |
|
rs121912665
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germline TP53 mutation c.566C>T results in the missense mutation GCC (Ala) to GTC (Val) at codon 189 (A189V) and has been reported in a case of multiple primary colon tumors.
|
23667851 |
2013 |
|
rs1057519803
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Oncogenic ERBB3 mutations in human cancers.
|
23680147 |
2013 |
|
rs2010963
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After stratifying by tumor molecular subtype, SNP associations observed for colon cancer were: VEGFA rs2010963 with CIMP+ colon tumors; FLT1 rs4771249 and rs7987649 with TP53; FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.
|
23794399 |
2014 |
|
rs4771249
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After stratifying by tumor molecular subtype, SNP associations observed for colon cancer were: VEGFA rs2010963 with CIMP+ colon tumors; FLT1 rs4771249 and rs7987649 with TP53; FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.
|
23794399 |
2014 |
|
rs7987649
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After stratifying by tumor molecular subtype, SNP associations observed for colon cancer were: VEGFA rs2010963 with CIMP+ colon tumors; FLT1 rs4771249 and rs7987649 with TP53; FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.
|
23794399 |
2014 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
In conclusion, BRAF (p.V600E) colon tumors showed significant MEIS1 promoter methylation, which was associated with decreased MEIS1 gene expression.
|
24244575 |
2013 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
In conclusion, BRAF (p.V600E) colon tumors showed significant MEIS1 promoter methylation, which was associated with decreased MEIS1 gene expression.
|
24244575 |
2013 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
rs397517132
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
rs113488022
|
|
T |
0.770 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913377
|
|
TT |
0.770 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs1064793236
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs587778966
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs587780053
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs63750206
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs730881913
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs768824654
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs779512948
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs864622553
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the colon tumor of the proband, MLH1 and PMS2 expression was completely lost as a consequence of a pathogenic somatic point mutation (MLH1 c.199G>A, p.Gly67Arg) that also abrogated local methylation by destroying a CpG site.
|
25742745 |
2015 |
|
rs17280262
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A genome wide association study on Newfoundland colorectal cancer patients' survival outcomes.
|
25866641 |
2015 |